Radiation therapy in the treatment of minor salivary gland tumors

Lucas R. Salgado, Daniel E. Spratt, Nadeem Riaz, Paul B. Romesser, Suzanne Wolden, Shyam Rao, Christine Chin, Julian C. Hong, Richard Wong, Nancy Y. Lee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: Minor salivary gland cancers are rare and account for roughly 2% to 3% of all head and neck tumors. This is a retrospective review in a modern cohort of patients treated for this rare cancer with surgery and adjuvant radiation therapy.

Materials and Methods: Between February 1990 and December 2010, 98 patients with cancer of the minor salivary glands were identified and treated at a single institution. The median radiation dose was 63 Gy. Outcomes assessed included local control (LC), locoregional control (LRC), and overall survival (OS). Toxicity was graded using the Common Terminology Criteria for Adverse Events, version 3.0. Competing-risk analysis using the Gray test was performed, with death as the competing risk. OS was calculated by the Kaplan-Meier method.

Results: With a median follow-up of 7.3 years, the 5- and 10-year LC and LRC rates were 87.9% and 83%, and 80.5% and 73.7%, respectively. Higher T stage and adenocarcinoma histology were the significant negative prognostic factors for both LC and LRC. Freedom from distant metastasis at 5 and 10 years were 83% and 63%, respectively. The median OS was 19.6 years. Overall, no grade 4 or 5 toxicities occurred, and 20% of the cohort experienced an acute grade 3 toxicity, and 6% with a grade 3 late toxicity.

Conclusions: In a modern cohort treated with surgery and radiotherapy, excellent outcomes can be achieved with lower toxicity rates compared with older published series.

Original languageEnglish (US)
Pages (from-to)492-497
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume37
Issue number5
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Minor Salivary Glands
Glandular and Epithelial Neoplasms
Salivary Gland Neoplasms
Radiotherapy
Survival
Terminology
Neoplasms
Histology
Adenocarcinoma
Neck
Therapeutics
Head
Radiation
Neoplasm Metastasis

Keywords

  • Cancer
  • Minor salivary gland
  • Radiation therapy
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Radiation therapy in the treatment of minor salivary gland tumors. / Salgado, Lucas R.; Spratt, Daniel E.; Riaz, Nadeem; Romesser, Paul B.; Wolden, Suzanne; Rao, Shyam; Chin, Christine; Hong, Julian C.; Wong, Richard; Lee, Nancy Y.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 37, No. 5, 01.01.2013, p. 492-497.

Research output: Contribution to journalArticle

Salgado, LR, Spratt, DE, Riaz, N, Romesser, PB, Wolden, S, Rao, S, Chin, C, Hong, JC, Wong, R & Lee, NY 2013, 'Radiation therapy in the treatment of minor salivary gland tumors', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 37, no. 5, pp. 492-497. https://doi.org/10.1097/COC.0b013e31827e54e5
Salgado, Lucas R. ; Spratt, Daniel E. ; Riaz, Nadeem ; Romesser, Paul B. ; Wolden, Suzanne ; Rao, Shyam ; Chin, Christine ; Hong, Julian C. ; Wong, Richard ; Lee, Nancy Y. / Radiation therapy in the treatment of minor salivary gland tumors. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2013 ; Vol. 37, No. 5. pp. 492-497.
@article{b1e0cecba4e349289205b91b261399a7,
title = "Radiation therapy in the treatment of minor salivary gland tumors",
abstract = "Purpose: Minor salivary gland cancers are rare and account for roughly 2{\%} to 3{\%} of all head and neck tumors. This is a retrospective review in a modern cohort of patients treated for this rare cancer with surgery and adjuvant radiation therapy.Materials and Methods: Between February 1990 and December 2010, 98 patients with cancer of the minor salivary glands were identified and treated at a single institution. The median radiation dose was 63 Gy. Outcomes assessed included local control (LC), locoregional control (LRC), and overall survival (OS). Toxicity was graded using the Common Terminology Criteria for Adverse Events, version 3.0. Competing-risk analysis using the Gray test was performed, with death as the competing risk. OS was calculated by the Kaplan-Meier method.Results: With a median follow-up of 7.3 years, the 5- and 10-year LC and LRC rates were 87.9{\%} and 83{\%}, and 80.5{\%} and 73.7{\%}, respectively. Higher T stage and adenocarcinoma histology were the significant negative prognostic factors for both LC and LRC. Freedom from distant metastasis at 5 and 10 years were 83{\%} and 63{\%}, respectively. The median OS was 19.6 years. Overall, no grade 4 or 5 toxicities occurred, and 20{\%} of the cohort experienced an acute grade 3 toxicity, and 6{\%} with a grade 3 late toxicity.Conclusions: In a modern cohort treated with surgery and radiotherapy, excellent outcomes can be achieved with lower toxicity rates compared with older published series.",
keywords = "Cancer, Minor salivary gland, Radiation therapy, Surgery",
author = "Salgado, {Lucas R.} and Spratt, {Daniel E.} and Nadeem Riaz and Romesser, {Paul B.} and Suzanne Wolden and Shyam Rao and Christine Chin and Hong, {Julian C.} and Richard Wong and Lee, {Nancy Y.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1097/COC.0b013e31827e54e5",
language = "English (US)",
volume = "37",
pages = "492--497",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Radiation therapy in the treatment of minor salivary gland tumors

AU - Salgado, Lucas R.

AU - Spratt, Daniel E.

AU - Riaz, Nadeem

AU - Romesser, Paul B.

AU - Wolden, Suzanne

AU - Rao, Shyam

AU - Chin, Christine

AU - Hong, Julian C.

AU - Wong, Richard

AU - Lee, Nancy Y.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Purpose: Minor salivary gland cancers are rare and account for roughly 2% to 3% of all head and neck tumors. This is a retrospective review in a modern cohort of patients treated for this rare cancer with surgery and adjuvant radiation therapy.Materials and Methods: Between February 1990 and December 2010, 98 patients with cancer of the minor salivary glands were identified and treated at a single institution. The median radiation dose was 63 Gy. Outcomes assessed included local control (LC), locoregional control (LRC), and overall survival (OS). Toxicity was graded using the Common Terminology Criteria for Adverse Events, version 3.0. Competing-risk analysis using the Gray test was performed, with death as the competing risk. OS was calculated by the Kaplan-Meier method.Results: With a median follow-up of 7.3 years, the 5- and 10-year LC and LRC rates were 87.9% and 83%, and 80.5% and 73.7%, respectively. Higher T stage and adenocarcinoma histology were the significant negative prognostic factors for both LC and LRC. Freedom from distant metastasis at 5 and 10 years were 83% and 63%, respectively. The median OS was 19.6 years. Overall, no grade 4 or 5 toxicities occurred, and 20% of the cohort experienced an acute grade 3 toxicity, and 6% with a grade 3 late toxicity.Conclusions: In a modern cohort treated with surgery and radiotherapy, excellent outcomes can be achieved with lower toxicity rates compared with older published series.

AB - Purpose: Minor salivary gland cancers are rare and account for roughly 2% to 3% of all head and neck tumors. This is a retrospective review in a modern cohort of patients treated for this rare cancer with surgery and adjuvant radiation therapy.Materials and Methods: Between February 1990 and December 2010, 98 patients with cancer of the minor salivary glands were identified and treated at a single institution. The median radiation dose was 63 Gy. Outcomes assessed included local control (LC), locoregional control (LRC), and overall survival (OS). Toxicity was graded using the Common Terminology Criteria for Adverse Events, version 3.0. Competing-risk analysis using the Gray test was performed, with death as the competing risk. OS was calculated by the Kaplan-Meier method.Results: With a median follow-up of 7.3 years, the 5- and 10-year LC and LRC rates were 87.9% and 83%, and 80.5% and 73.7%, respectively. Higher T stage and adenocarcinoma histology were the significant negative prognostic factors for both LC and LRC. Freedom from distant metastasis at 5 and 10 years were 83% and 63%, respectively. The median OS was 19.6 years. Overall, no grade 4 or 5 toxicities occurred, and 20% of the cohort experienced an acute grade 3 toxicity, and 6% with a grade 3 late toxicity.Conclusions: In a modern cohort treated with surgery and radiotherapy, excellent outcomes can be achieved with lower toxicity rates compared with older published series.

KW - Cancer

KW - Minor salivary gland

KW - Radiation therapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84914670452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914670452&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e31827e54e5

DO - 10.1097/COC.0b013e31827e54e5

M3 - Article

C2 - 23428950

AN - SCOPUS:84914670452

VL - 37

SP - 492

EP - 497

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -